Ipsen Manufacturing
Ipsen is a biotechnological group aiming to become a leader in specialty healthcare solutions for debilitating diseases. Its strategy is supported by three franchises, neurology, endocrinology and urology-oncology.
Ipsen has a growing portfolio in prostate cancer, bladder cancer or neuro-endocrine tumours and a presence in primary care.
The group has more than 4,500 employees spread across R&D and manufacturing sites located in China, France, Ireland, the UK and the US.
Financial Data
-
31st Dec 15 Source: CRO
- €89.4 million turnover
-
€74.3 million
profit - 99 employees
-
31st Dec 14 Source: CRO
- €66.5 million turnover
-
€52.9 million
profit - 94 employees
- 3 more years available »
Ranking
By Turnover
(€89.4 million)- 501st in Top Companies
- 55th in Health
- 55th in Pharma
- 74th in Manufacturing
By Employees
(99)- 716th in Top Companies
- 89th in Health
- 73rd in Pharma
- 112th in Manufacturing
- 99
- €89.4 million
Employees
- James Byrne General Manager